Back to Authors

Khazaie, Khashayarsha

0000-0002-7884-1817

Mayo Clinic

Department of Immunology, Mayo Clinic, Rochester, Minnesota.

Citations 5

Maternal obesity induces developmental programming of Intestinal stem cells through an IL-17A/PPAR immune-epithelial axis
Lahiri, Gourab , Millan, Yesenia Barrera, Sankar, Swathi , Mullen, Karla F, McDermott, Thomas Hartley, Saiz, Dominic R. , Farnsworth, Fiona , Torel, Matt , Blatt, Madeline , Roginski, Ana Cristina , Shukla, Abhigyan, Florsheim, Esther Borges , Khazaie, Khashayarsha , Barrera Millan, Yesenia , Sankar, Swathi , Mullen, Karla , Hartley McDermott, Thomas , Florsheim, Esther , Bartelle, Benjamin B , Khazaie, Khashayarsha , Gounari, Fotini , Mana, Miyeko D , Bartelle, Benjamin B. , Gounari, Fotini

No container title available | March 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.15.711939 Get It

ABSTRACT Maternal obesity is associated with increased risk of sporadic colorectal cancer (CRC) in offspring, suggesting that early-life environmental exposures durably shape disease susceptibility. Intestinal stem cells (ISCs), long-lived drivers of epithelial renewal and tumor initiation, are well poised to mediate this effect; however, how maternal obesity influences ISC programming during development remains poorly understood. Using mouse models of diet-induced obesity, we show that exposure to a maternal high-fat Western diet (mHFD) during pre- and postnatal development stably programs colonic ISCs. Offspring exhibit increased ISC proliferation, enhanced self-renewal, a hypermetabolic state, and altered epithelial lineage composition that persists into adulthood despite dietary normalization. These changes are accompanied by increased tumor burden following loss of Apc heterozygosity. Mechanistically, we identify the pro-inflammatory cytokine IL-17A as a key extrinsic driver and PPARd/a nuclear receptors as intrinsic mediators of the mHFD phenotype, revealing an immune-epithelial axis that programs ISC function during early life. Together, our findings demonstrate that maternal metabolic environments durably enhance stem cell fitness, providing a mechanistic link between developmental exposure and adult disease risk.
Colon Organoids as Experimental Models to Study the Effect of Micro-Nanoparticles as a Driver of Early-Onset Colon Cancer
Heydari, Zahra , Sarkar, Gobinda , Helgeson, Lauren, Garcia, Edwin , Ros, Alexandra , Khazaie, Khashayarsha , Boardman, Lisa, Cruz Garcia, Estela Mariel , Khazaie, Khashayarsha , Boardman, Lisa

Cells | December 26, 2025 | Volume: 15 | Issue: 1 | Pages: 40

10.3390/cells15010040 Get It

Early-onset colorectal cancer (EOCRC) in people < 50 years of age has been rising globally, yet its causes remain unknown. Emerging evidence suggests that environmental factors, including exposure to micro-and nanoplastics (MNPs), may contribute to colorectal carcinogenesis. MNPs can enter the gastrointestinal tract through ingestion, translocate across the epithelial barrier via endocytosis or paracellular pathways, and interact directly with epithelial and immune cells. Once internalized, they may generate events associated with tumor initiation including oxidative stress, disruption of membrane integrity, pro-inflammatory signaling, and disruption of genomic and epigenomic stability. Patient-derived colorectal organoids offer a physiologically relevant and scalable 3D model that closely mimics the cellular architecture and genetic landscape of primary tumors. We highlight how organoid models can be leveraged to study the impact of MNPs on the key processes of inflammation, DNA damage, senescence, and epigenetic modifications. Furthermore, we discuss the application of organoid-based systems to model EOCRC driven by environmental exposures, including the integration of organoid platforms with high-throughput assays, omics profiling, and microfluidics to better capture MNP-induced pathogenic mechanisms. Altogether, colorectal organoids provide a powerful bridge between environmental plastic exposure and EOCRC etiology, offering a tractable platform to identify mechanistic pathways and potential biomarkers of early disease.
Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi -NT in Patients with Advanced Solid Tumors
Nelson, Blessie Elizabeth , Jankú, Filip , Fu, Siqing , Dumbrava, Ecaterina E. , Hong, David S. , Karp, Daniel D. , Naing, Aung , Tsimberidou, Apostolia M. , Murthy, Ravi , Sheth, Rahul A. , Amaria, Rodabe N. , Carapanceanu, Nicoleta, Singh, Mahendra Pal , Carapanceanu, Valentin, Pezeshki, Abdulmohammad , Leontovich, Alexey A. , Kreider, Brent L. , Tung, David, Varterasian, Mary , Khazaie, Khashayarsha , Piha‐Paul, Sarina A. , Rodon, Jordi , Tsimberidou, Apostolia Maria , Murthy, Ravi , Sheth, Rahul A , Amaria, Rodabe N , Conley, Anthony P , Damodaran, Senthil , Raghav, Kanwal P S , Carapanceanu, Nicoleta , Singh, Mahendra Pal , Carapanceanu, Valentin , Pezeshki, Abdulmohammad , Kreider, Brent , Tung, David , Varterasian, Mary , Khazaie, Khashayarsha , Piha-Paul, Sarina A , Hong, David S , Conley, Anthony P. , Raghav, Kanwal

Clinical Cancer Research | July 11, 2025 | Volume: 31 | Issue: 18 | Pages: 3864-3875

10.1158/1078-0432.ccr-24-3952 Get It

Abstract Purpose: Intratumoral injection of Clostridium novyi-nontoxic (C. novyi-NT), lacking alpha-toxin, germinates and subsequently replicates in the tumor hypoxic regions, causing cell lysis and inflammation. This phase Ib study investigated the safety and synergistic effects of pembrolizumab and C. novyi-NT in advanced solid tumors. Patients and Methods: Patients with injectable solid tumors received one intratumoral C. novyi-NT injection (day 8) across four dose cohorts (3 × 104 to 100 × 104 spores) with pembrolizumab (200 mg intravenously every 3 weeks, day 0–24 months). Sixteen patients were enrolled with a median age of 62.5 years, and the most common tumor types were breast cancer and melanoma. Results: The combination therapy demonstrated a manageable safety profile, with one grade 3 dose-limiting toxicity of abscess formation and the remainder of treatment-related adverse events in ≥10% of patients being grade 1 or 2 injection site reaction (25%), pyrexia (19%), pruritus (13%), leukopenia (13%), and anemia (13%). The maximum tolerated dose was determined to be pembrolizumab intravenously at 200 mg every 3 weeks and a single dose of 100 × 104C.novyi-NT spores intratumorally on day 8. The confirmed overall objective response rate of 25% was observed among four patients with nonkeratinizing undifferentiated nasopharyngeal squamous carcinoma, human papilloma virus–positive squamous cell carcinoma of the base of the tongue, vulvar melanoma, and chordoma. Among these patients, we obtained three partial responses and one complete response. The median duration of the response was 10.93 months, and stable disease was observed in 69% of patients. Conclusions: This study highlights the potential of the C. novyi-NT and pembrolizumab combination as a promising therapeutic strategy for treatment-refractory solid tumors.
Colorectal cancer-associated microbiota contributes to oncogenic epigenetic signatures
Sobhani, Iradj , Bergsten, Emma , Couffin, Séverine , Amiot, Aurélien , Nebbad, Biba, Barau, Caroline , de’Angelis, Nicola , Mestivier, Denis , Pédron, Thierry , Khazaie, Khashayarsha , Sansonetti, Philippe , Khazaie, Khashayarsha , Rabot, Sylvie , Canouï‐Poitrine, Florence

Proceedings of the National Academy of Sciences | November 11, 2019 | Volume: 116 | Issue: 48 | Pages: 24285-24295

10.1073/pnas.1912129116 Get It

Sporadic colorectal cancer (CRC) is a result of complex interactions between the host and its environment. Environmental stressors act by causing host cell DNA alterations implicated in the onset of cancer. Here we investigate the stressor ability of CRC-associated gut dysbiosis as causal agent of host DNA alterations. The epigenetic nature of these alterations was investigated in humans and in mice. Germ-free mice receiving fecal samples from subjects with normal colonoscopy or from CRC patients were monitored for 7 or 14 wk. Aberrant crypt foci, luminal microbiota, and DNA alterations (colonic exome sequencing and methylation patterns) were monitored following human feces transfer. CRC-associated microbiota induced higher numbers of hypermethylated genes in murine colonic mucosa (vs. healthy controls’ microbiota recipients). Several gene promoters including SFRP1,2,3, PENK, NPY, ALX4, SEPT9, and WIF1 promoters were found hypermethylated in CRC but not in normal tissues or effluents from fecal donors. In a pilot study ( n = 266), the blood methylation levels of 3 genes ( Wif1 , PENK , and NPY ) were shown closely associated with CRC dysbiosis. In a validation study ( n = 1,000), the cumulative methylation index (CMI) of these genes was significantly higher in CRCs than in controls. Further, CMI appeared as an independent risk factor for CRC diagnosis as shown by multivariate analysis that included fecal immunochemical blood test. Consequently, fecal bacterial species in individuals with higher CMI in blood were identified by whole metagenomic analysis. Thus, CRC-related dysbiosis induces methylation of host genes, and corresponding CMIs together with associated bacteria are potential biomarkers for CRC.
Mast cells promote small bowel cancer in a tumor stage-specific and cytokine-dependent manner
Osman, Abu , Gurish, Michael F. , Dennis, Kristen L., Blatner, Nichole R., Pezeshki, Abdulmohammad , McNagny, Kelly M. , Cheroutre, Hilde , Gounari, Fotini , Khazaie, Khashayarsha , Saadalla, Abdulrahman M, McNagny, Kelly M , Khazaie, Khashayarsha , Saadalla, Abdulrahman , Gounari, Fotini

Proceedings of the National Academy of Sciences | February 2, 2018 | Volume: 115 | Issue: 7 | Pages: 1588-1592

10.1073/pnas.1716804115 Get It

Significance We show that distinct subsets of mast cells (MCs) expand with sequential oncogenic events in small bowel cancer. Mucosal mast cells (MMCs) previously detected early during Trichinella spiralis infection expand in adenomatous polyps in an IL-10–dependent manner. Connective tissue mast cells (CTMCs), earlier shown to expand during the resolution of inflammation following clearance of T. spiralis, are independent of IL-10 and associate with the transition of polyps to adenocarcinoma. IL-33 upregulates the CTMC lineage-specific protease murine mast cell protease 6 (mMCP6). Ablation of mMCP6 attenuates tumor growth. Thus, tissue sentinel cells respond to oncogenic events and cellular transformation in effect to help promote cancer. Delineating the types of MCs present at various stages of disease offers actionable cellular targets for therapeutic intervention in disease progression.